In last trading session, Verrica Pharmaceuticals Inc (NASDAQ:VRCA) saw 0.78 million shares changing hands with its beta currently measuring 1.73. Company’s recent per share price level of $0.53 trading at $0.11 or 26.21% at ring of the bell on the day assigns it a market valuation of $48.66M. That closing price of VRCA’s stock is at a discount of -2052.83% from its 52-week high price of $11.41 and is indicating a premium of 28.3% from its 52-week low price of $0.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 379.44K if we extend that period to 3-months.
For Verrica Pharmaceuticals Inc (VRCA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) trade information
Upright in the green during last session for gaining 26.21%, in the last five days VRCA remained trading in the green while hitting it’s week-highest on Friday, 04/04/25 when the stock touched $0.53 price level, adding 1.56% to its value on the day. Verrica Pharmaceuticals Inc’s shares saw a change of -24.27% in year-to-date performance and have moved 22.42% in past 5-day. Verrica Pharmaceuticals Inc (NASDAQ:VRCA) showed a performance of -14.31% in past 30-days. Number of shares sold short was 2.22 million shares which calculate 6.18 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 95.58% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -1786.79% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1786.79% for stock’s current value.
Verrica Pharmaceuticals Inc (VRCA) estimates and forecasts
This year revenue growth is estimated to rise 114.39% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.61M for the same. And 6 analysts are in estimates of company making revenue of 3.53M in the next quarter. Company posted 3.83M and 5.18M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -5.46% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 71.49% while estimates for its earnings growth in next 5 years are of 43.28%.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA)’s Major holders
Insiders are in possession of 43.30% of company’s total shares while institution are holding 32.65 percent of that, with stock having share float percentage of 57.57%. Investors also watch the number of corporate investors in a company very closely, which is 32.65% institutions for Verrica Pharmaceuticals Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at VRCA for having 7.1 million shares of worth $51.75 million. And as of 2024-06-30, it was holding 15.2663 of the company’s outstanding shares.
The second largest institutional holder is AVORO CAPITAL ADVISORS LLC, which was holding about 4.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6017 of outstanding shares, having a total worth of $29.16 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.3 shares of worth $0.69 million or 1.41% of the total outstanding shares. The later fund manager was in possession of 539.31 shares on Feb 28, 2025 , making its stake of worth around $0.29 million in the company or a holder of 0.59% of company’s stock.
